By Doug Macron

RXi Pharmaceuticals last week announced that it had selected a lead candidate from its anti-scarring program as the first compound it will move into human testing, meeting a previously stated corporate goal for 2010.

And while company's other goal for the year — the establishment of an industry partnership — remains an overall objective, RXi President and CEO Noah Beerman indicated that it may not happen until 2011.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In Genome Research this week: multiplex genotyping of germline and somatic short tandem repeats, graph-based regularization, and more.

A lack of funding may lead more than two dozen research facilities in Australia to shut down in three months.

Researchers report that paternally inherited genes are more likely to be expressed in mice.

National Institutes of Health Director Francis Collins appears before a House subcommittee to discuss his agency's budget request.